Flashner-Barak; Moshe
Patent Applications and Registrations
Patent applications and USPTO patent grants for Flashner-Barak; Moshe.The latest application filed is for "formulations of 6-mercaptopurine".
Company Profile
1.11.42
- Flashner-Barak; Moshe - Petach-Tikva IL
Patent Activity
| Patent | Date |
|---|---|
| Formulations of 6-mercaptopurine Grant 10,525,009 - Lerner , et al. J | 2020-01-07 |
| Formulations Of 6-mercaptopurine App 20160296473 - Lerner; E. Itzhak ; et al. | 2016-10-13 |
| Formulations of 6-mercaptopurine Grant 9,375,403 - Lerner , et al. June 28, 2 | 2016-06-28 |
| Formulations of 6-mercaptopurine Grant 9,180,097 - Lerner , et al. November 10, 2 | 2015-11-10 |
| Formulations Of 6-mercaptopurine App 20150290133 - Lerner; E. Itzhak ; et al. | 2015-10-15 |
| Risperidone microparticles formed by sublimation Grant 9,107,832 - Lerner , et al. August 18, 2 | 2015-08-18 |
| Formulations Of 6-mercaptopurine App 20140161888 - Lerner; E. Itzhak ; et al. | 2014-06-12 |
| Drug Microparticles App 20140134256 - LERNER; E. Itzhak ; et al. | 2014-05-15 |
| Drug microparticles, processes of preparing them and a drug delivery vehicle comprising them Grant 8,663,703 - Lerner , et al. March 4, 2 | 2014-03-04 |
| Formulations of 6-mercaptopurine Grant 8,653,060 - Lerner , et al. February 18, 2 | 2014-02-18 |
| Formulations Of 6-mercaptopurine App 20120207841 - Lerner; E. Itzhak ; et al. | 2012-08-16 |
| Formulations of 6-mercaptopurine Grant 8,188,067 - Lerner , et al. May 29, 2 | 2012-05-29 |
| Drug Microparticles App 20100092568 - Lerner; E. Itzhak ; et al. | 2010-04-15 |
| Therapy using a combination of raloxifene and alendronate Grant 7,579,333 - Lerner , et al. August 25, 2 | 2009-08-25 |
| Delayed release formulations of 6-mercaptopurine App 20090042914 - Lerner; E. Itzhak ; et al. | 2009-02-12 |
| Drug microparticles App 20080057129 - Lerner; E. Itzhak ; et al. | 2008-03-06 |
| Levodopa compositions App 20070178149 - Flashner-Barak; Moshe ; et al. | 2007-08-02 |
| Pharmaceutical formulations of fenofibrate having improved bioavailability App 20070148233 - Lerner; E. Itzhak ; et al. | 2007-06-28 |
| Tizanidine compositions and methods of treatment using the compositions App 20070078174 - Flashner-Barak; Moshe ; et al. | 2007-04-05 |
| Formulations of fenofibrate containing PEG/Poloxamer App 20070015834 - Flashner-Barak; Moshe ; et al. | 2007-01-18 |
| Formulations of fenofibrate containing menthol App 20070015833 - Flashner-Barak; Moshe ; et al. | 2007-01-18 |
| Controlled released dosage forms App 20060233879 - Lerner; E. Itzhak ; et al. | 2006-10-19 |
| Controlled release dosage forms App 20060233880 - Lerner; E. Itzhak ; et al. | 2006-10-19 |
| Formulations of fenofibrate App 20060222707 - Lerner; E. Itzhak ; et al. | 2006-10-05 |
| Formulations of Fenofibrate App 20060222706 - Flashner-Barak; Moshe ; et al. | 2006-10-05 |
| Dosage forms with an enterically coated core tablet App 20060153918 - Lerner; E. Itzhak ; et al. | 2006-07-13 |
| Drug microparticles App 20060141050 - Lerner; Itzhak E. ; et al. | 2006-06-29 |
| Cyclosporin formulations App 20060141028 - Flashner-Barak; Moshe ; et al. | 2006-06-29 |
| Drug microparticles App 20060141051 - Lerner; E. Itzhak ; et al. | 2006-06-29 |
| Drug microparticles App 20060141052 - Lerner; E. Itzhak ; et al. | 2006-06-29 |
| Pharmaceutical dosage forms including rasagiline App 20060018957 - Lerner; E. Itzhak ; et al. | 2006-01-26 |
| Delayed release formulations of 6-mercaptopurine App 20060008520 - Lerner; E. Itzhak ; et al. | 2006-01-12 |
| Formulations of 6-mercaptopurine App 20060009473 - Lerner; E. Itzhak ; et al. | 2006-01-12 |
| Therapy using a combination of raloxifene and alendronate App 20050282784 - Lerner, E. Itzhak ; et al. | 2005-12-22 |
| Simvastatin formulations and methods of making same App 20050192340 - Flashner-Barak, Moshe ; et al. | 2005-09-01 |
| Nanoparticles for drug delivery App 20050170004 - Rosenberger, Vered ; et al. | 2005-08-04 |
| Composition and dosage form for sustained effect of levodopa App 20050113452 - Flashner-Barak, Moshe ; et al. | 2005-05-26 |
| Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation Grant 6,881,420 - Flashner-Barak , et al. April 19, 2 | 2005-04-19 |
| Compositions and dosage forms for gasteric delivery of antineoplastic agents and methods of treatment that use them to inhibit cancer cell proliferation App 20050048086 - Flashner-Barak, Moshe ; et al. | 2005-03-03 |
| Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative App 20050026871 - Flashner-Barak, Moshe ; et al. | 2005-02-03 |
| Menthol solutions of drugs App 20040198646 - Flashner-Barak, Moshe ; et al. | 2004-10-07 |
| Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or buccally App 20040122065 - Lerner, E. Itzhak ; et al. | 2004-06-24 |
| Microparticle pharmaceutical compositions for intratumoral delivery App 20040092577 - Lerner, E. Itzhak ; et al. | 2004-05-13 |
| Controlled release dosage forms App 20040052843 - Lerner, E. Itzhak ; et al. | 2004-03-18 |
| Drug microparticles App 20030224059 - Lerner, E. Itzhak ; et al. | 2003-12-04 |
| Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates App 20030203878 - Flashner-Barak, Moshe ; et al. | 2003-10-30 |
| Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents App 20020041888 - Flashner-Barak, Moshe | 2002-04-11 |
| Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates App 20020015733 - Flashner-Barak, Moshe ; et al. | 2002-02-07 |
| Method of administration of paclitaxel-plasma protein formulation App 20010056070 - Flashner-Barak, Moshe | 2001-12-27 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 